Author(s): Neal JW, Gubens MA, Wakelee HA
Abstract Share this page
Abstract Confined to one side of the chest, limited stage small cell lung cancer is treated with a combination of chemotherapy and radiotherapy, yet has a long-term survival rate of only 15\%. Extensive stage disease has initial response rates to chemotherapy exceeding 70\%. However, the disease almost invariably progresses and becomes fatal. Many recent clinical trials have failed to show superiority of newer chemotherapeutics or targeted therapies compared with the standard chemotherapy backbone of platinum plus etoposide. Numerous promising targeted therapies and other agents are still in development. Copyright Â© 2011 Elsevier Inc. All rights reserved.
This article was published in Clin Chest Med
and referenced in Journal of Clinical & Experimental Pathology